Clozapine case series

Psychosomatics

Volumn 48, Issue 2, 2007, Pages 170-175

  Sandson, Neil B ^a   Cozza, Kelly L ^a   Armstrong, Scott C ^a   Eckermann, Gabriel ^a   Fischer, Bernard A ^a   Phillips, Barnell ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; CIMETIDINE; CIPROFLOXACIN; CLOZAPINE; CYTOCHROME P450; DIPHENHYDRAMINE; ETHINYLESTRADIOL; FLUOXETINE; HALOPERIDOL; LORAZEPAM; OLANZAPINE; QUETIAPINE; TIOTIXENE; ZIPRASIDONE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; MENTAL DISEASE; MENTAL PATIENT; ORAL CONTRACEPTION; PARANOID SCHIZOPHRENIA; POLYPHARMACY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; URINARY TRACT INFECTION;

EID: 33847645430     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.48.2.170     Document Type: Article

References (39)

1. Lewis SW, Barnes TR, Davies L, et al: Randomized, controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32:715-723
2. Olesen OV, Linnet K: Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000; 20:35-42
3. Eiermann B, Engel G, Johansson I, et al: The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44:439-46
4. Olesen OV, Linnet K: Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41:823-32
5. Breyer-Pfaff U, Wachsmuth H: Tertiary N-glucuronides of clozapine and its metabolite, desmethylclozapine, in patient urine. Drug Metab Dispos 2001; 29:1343-1348
6. Boulton DW, DeVane CL, Liston HL, et al: In-vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71:163-169
7. Shin JG, Soukhova N, Flockhart DA: Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999; 27:1078-1084
8. Smith T, Riskin J: Effect of clozapine on plasma nortriptyline concentration. Pharmacopsychiatry 1994; 27:41-42
9. Crewe HK, Lennard MS, Tucker GT, et al: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34:262-265
10. Stevens JC, Wrighton SA: Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993; 266:964-971
11. von Moltke LL, Greenblatt DJ, Duan SX, et al: Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology (Berl) 1996; 128:398-407
12. Hesse LM, Venkatakrishnan K, Court MH, et al: CYP2B6 mediates the in-vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28:1176-1183
13. Sayal KS, Duncan-McConnell DA, McConnell HW, et al: Psychotropic interactions with warfarin. Acta Psychiatr Scand 2000; 102:250-255
14. Kobayashi K, Yamamoto T, Chiba K, et al: The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40:481-485
15. Hemeryck A, Belpaire FM: Selective serotonin reuptake inhibitors and cytochrome P450-mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3:13-37
16. von Moltke LL, Greenblatt DJ, Harmatz JS, et al: Triazolam bio-transformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276:370-379
17. Weiss J, Dormann SM, Martin-Facklam M, et al: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305:197-204
18. Spina E, Avenoso A, Facciola G, et al: Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13:141-145
19. Hemeryck A, Belpaire FM: Selective serotonin reuptake inhibitors and cytochrome P450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3:13-37
20. Christensen M, Tybring G, Mihara K, et al: Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002; 71:141-152
21. Heeringa M, Beurskens R, Schouten W, et al: Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 1999; 21:243-244
22. Jerling M, Lindstrom L, Bondesson U, et al: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16:368-374
23. Szegedi A, Anghelescu I, Wiesner J, et al: Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999; 32:148-153
24. Wetzel H, Anghelescu I, Szegedi A, et al: Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18:2-9
25. Batty KT, Davis TM, Ilett KF, et al: The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995; 39:305-311
26. Granfors MT, Backman JT, Neuvonen M, et al: Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1 A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004; 76:598-606
27. Hedaya MA, El-Afify DR, El-Maghraby GM: The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharm Drug Dispos 2006; 27:103-110
28. Raaska K, Neuvonen PJ: Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000; 56:585-589
29. Granfors MT, Backman JT, Laitila J, et al: Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005; 78:400-411
30. Shelepova T, Nafziger AN, Victory J, et al: Effect of triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5 + 1 cocktail. J Clin Pharmacol 2005; 45:1413-1421
31. 2- receptor antagonists. Clin Pharmacol Ther 1999; 65:369-376
32. Nation RL, Evans AM, Milne RW: Pharmacokinetic drug interactions with phenytoin, part 1. Clin Pharmacokinet 1990; 18:37-60
33. Szymanski S, Lieberman JA, Picou D, et al: A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991; 52:21-22
34. Schrenk D, Brockmeier D, Morike K, et al: A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort study of healthy Caucasian volunteers. Eur J Clin Pharmacol 1998; 53:361-367
35. Zevin S, Benowitz NL: Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999; 36:425-438
36. Rostami-Hodjegan A, Amin AM, Spencer EP, et al: Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and assess compliance in individual patients. J Clin Psychopharmacol 2004; 24:70-78
37. Haslemo T, Eikeseth PH, Tanum L, et al: The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62:1049-1053
38. Meyer JM: Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 2001; 21:569-574
39. Zullino DF, Delessert D, Eap CB, et al: Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17:141-143